Scarica l'app Stockscreener
1.74
1.69%
-0.03
Pre-mercato:
1.73
-0.01
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OPK Giù?
Forum
Previsione
Precedente Chiudi:
$1.77
Aprire:
$1.78
Volume 24 ore:
2.13M
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.20B
Reddito:
$711.41M
Utile/perdita netta:
$-133.73M
Rapporto P/E:
-9.1579
EPS:
-0.19
Flusso di cassa netto:
$-199.99M
1 W Prestazione:
-4.40%
1M Prestazione:
+6.75%
6M Prestazione:
+14.47%
1 anno Prestazione:
+62.62%
Intervallo 1D:
$1.73
$1.80
Intervallo di 1 settimana:
$1.73
$1.8275
Portata 52W:
$1.12
$2.035
Opko Health Inc Stock (OPK) Company Profile
Nome
Opko Health Inc
Settore
Industria
Telefono
305-575-4181
Indirizzo
4400 BISCAYNE BLVD., MIAMI, FL
Confronta OPK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.74 | 1.20B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
511.68 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.11 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
422.54 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
118.97 | 33.93B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
179.36 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-06-29 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-11-25 | Iniziato | Piper Jaffray | Overweight |
| 2018-03-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Reiterato | Standpoint Research | Buy |
| 2016-06-03 | Iniziato | Standpoint Research | Buy |
| 2016-03-31 | Reiterato | Barrington Research | Outperform |
| 2015-10-16 | Iniziato | JP Morgan | Overweight |
| 2015-09-11 | Downgrade | Jefferies | Buy → Hold |
| 2015-03-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Reiterato | Oppenheimer | Outperform |
| 2014-03-14 | Iniziato | Oppenheimer | Outperform |
| 2013-11-13 | Reiterato | Ladenburg Thalmann | Buy |
| 2013-05-30 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-10-22 | Iniziato | Barrington Research | Outperform |
| 2011-12-01 | Reiterato | Ladenburg Thalmann | Buy |
| 2011-07-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Opko Health Inc Borsa (OPK) Ultime notizie
Charles Schwab Investment Management Inc. Has $5.14 Million Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat
OPKO Health Insider Ups Holding During Year - Simply Wall St
Quote - OPKO Health, Inc.
HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled - MSN
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat
PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.
Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance
H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma
Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga
Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker
OPKO and Entera partner to develop obesity pill - Reuters
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN
OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey
HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research - Defense World
10 Best Stocks Under $3 to Buy Now - Insider Monkey
H.C. Wainwright maintains $3 target on Opko Health stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $3 target on Opko Health stock - Investing.com
Opko Health Inc Azioni (OPK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Opko Health Inc Azioni (OPK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 29 '24 |
Buy |
1.53 |
199,072 |
305,376 |
211,911,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 22 '24 |
Buy |
1.59 |
100,000 |
159,000 |
211,712,405 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 14 '24 |
Buy |
1.62 |
100,000 |
161,980 |
211,612,405 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 08 '24 |
Buy |
1.50 |
280,183 |
421,535 |
211,512,405 |
0.37%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):